Skip to content

SmallCap Round Up: Verici DX, Oncimmune, Rockfire Resources


London’s AIM Index received a second boost on Wednesday following that softer than expected UK inflation print this morning, with the All Share adding a further five points to reach the bell at 715.61.

  • Verici DX +74%
  • Oncimmune +24%
  • Rockfire Resources +23%
  • Aurrigo International -27%
  • Amte Power -23%

Verici DX LON:VRCI was at the top of the pile on Wednesday, adding 74% by the bell after the company released news of a commercialisation agreement with Thermo Fischer Scientific. Verici offers a diagnostic test that can offer pre-transplant prognostic testing to reduce the rejection rate of organ transplants. Payments over the next 12 months to Verici are expected to total $5m with further payments and royalties due thereafter.

Oncimmune LON:ONC added 24% in what looked to be fairly lumpy trade. There’s no news out and the buying demand has left the closing spread around the 6% mark, and with the stock languishing near all time lows, it seems that some investors are now seeing value.

The notable mention goes to Rockfire Resources LON:ROCK, adding 23% on the day after two consecutive days of meaningful losses. The company notified the market today that a farm in partner had started drilling at a site in Australia, offering some support after what has been a torrid few days. Is this a turning point?

Aurrigo International [LON:AURR] dipped 27% on the day, making for the worst performer on AIM. That comes off the back of a discounted placing which completed today and the use of the funds is well laid out in today’s RNSm including investment in both staff and additional IT.

Amte Power LON:AMTE was in second to last place, down a further 23%. The company issued a fresh placing update today, noting that cashflow remained incredibly tight with only around two weeks funding remaining. This won’t be sufficient to last through the current planned placing round however so if an interim solution can’t be found, shareholders risk being wiped out.

Looking for great investing ideas? Sign up to our free newsletter.

Join us on WhatsApp

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

CME Group
FP Markets
Back To Top